Enterprise Value
-27.06M
Cash
284.3M
Avg Qtr Burn
-28.07M
Short % of Float
8.25%
Insider Ownership
25.36%
Institutional Own.
63.44%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
FHD-286 + decitabine or low-dose cytarabine (LDAC) Details Myelodysplastic syndrome, Acute myeloid leukemia | Phase 1 Data readout | |
FHD-609 Details Synovialsarcoma, Sarcoma | Failed Discontinued |